Zhejiang Hisoar Pharmaceutical Valuation

Is 002099 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002099 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002099 (CN¥5.76) is trading above our estimate of fair value (CN¥2.56)

Significantly Below Fair Value: 002099 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002099?

Key metric: As 002099 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 002099. This is calculated by dividing 002099's market cap by their current revenue.
What is 002099's PS Ratio?
PS Ratio	4.7x
Sales	CN¥1.94b
Market Cap	CN¥9.09b

002099 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.5x
Enterprise Value/EBITDA	48.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 002099's PS Ratio compare to its peers?

The above table shows the PS ratio for 002099 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.4x
688658 Youcare Pharmaceutical Group	2.2x	10.5%	CN¥9.1b
300363 Porton Pharma Solutions	3.4x	20.6%	CN¥9.4b
600267 Zhejiang Hisun Pharmaceutical	1x	2.6%	CN¥9.8b
002626 Xiamen Kingdomway Group	3.1x	18.4%	CN¥9.5b
002099 Zhejiang Hisoar Pharmaceutical	4.7x	n/a	CN¥9.1b

Price-To-Sales vs Peers: 002099 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the peer average (2.4x).

Price to Sales Ratio vs Industry

How does 002099's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$758.98m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$399.76m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 002099 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 002099's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002099 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002099's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

2.2%

7.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

-2.4%

12.8%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.91

-1.8%

14.6%